Properties of calprotectin


Andersson KB, Sletten K, Berntzen HB, Dale I, Brandtzaeg P, Jellum E, Fagerhol MK. The leucocyte L1 protein: identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol 1988; 28(2): 241-5.

PMID#: 3413449

 

Berntzen HB, Fagerhol MK. L1, a major granulocyte protein: antigenic properties of its subunits. Scand J Clin Lab Invest 1988; 48(7): 647-52.

PMID#: 3144035

 

Berntzen HB, Fagerhol MK. L1, a major granulocyte protein; isolation of high quantities of its subunits. Scand J Clin Lab Invest 1990; 50(7):769-74.

PMID#: 2293338

 

Brandtzaeg P, Gabrielsen TO, Dale I, Muller F, Steinbakk M, Fagerhol MK. The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor in epithelial surfaces. Adv Exp Med Biol 1995; 371A: 201-6.

PMID#: 8525906

 

Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol 1994; 21(4): 733-8.

PMID#: 8035402

 

Brun JG, Ulvestad E, Fagerhol MK, Jonsson R. Effects of human calprotectin (L1) on in vitro immunoglobulin synthesis. Scand J Immunol 1994; 40(6): 675-80.

PMID#: 7997858

 

Clohessy PA, Golden BE. Calprotectin-mediated zinc chelation as a biostatic mechanism in host defence. Scand J Immunol 1995; 42(5):551-6.

PMID#: 7481561

 

Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Europ J Biochem 1983; 134(1): 1-6.

PMID#: 6861753

 

Fagerhol MK, Dale I, Andersson T. Release and quantitation of a leukocyte derived protein (L1). Scand J Haematol 1980; 24: 393-8.

 

Fagerhol MK. Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein ? J Clin Pathol 1996; 49: 74-79

 

Mambula SS, Simons ER, Hastey R, Selsted ME, Levitz SM. Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans. Infection & Immunity 2000; 68(11): 6257-64.

PMID#: 11035733

 

Nisapakultorn K, Ross KF, Herzberg MC. Calprotectin expression inhibits bacterial binding to mucosal epithelial cells. Infect Immun 2001; 69(6): 3692-96.

PMID#: 11349032

 

Okutomi T, Tanaka T, Yui S, Mikami M, Yamazaki M, Abe S, Yamaguchi H. Anti-Candida activity of calprotectin in combination with neutrophils or lectoferrin. Microbiol Immunol 1998; 42(11): 789-93.

PMID#: 9886152

 

Pechkovsky DV, Zalutskaya OM, Ivanov GI, Misuno NI. Calprotectin (MRP8/14 protein complex) release during mycobacterial infection in vitro and in vivo. FEMS Immunol Med Microbiol 2000; 29(1): 27-33.

PMID#: 10967257

 

Sohnle PG, Hahn BL. Effect of zinc-reversible growth-inhibitory activity in human empyema fluid on antibiotic microbicidal activity. Antimicrob Agents Chemother 2000; 44(1):139-42.

PMID#: 10602735

 

Sohnle PG, Hunter MJ, Hahn B, Chazin WJ. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J Infect Dis 2000; 182(4):1272-5.

PMID#: 10979933



Next page: Distribution in the body  Previous page: Articles


Latest News

NEW AND IMPROVED ELISA

Calpro launches a new and improved ELISA for calprotectin!

Upcoming Events

ECCO 2012

February 16-18

Barcelona in Spain

Contact Information

Calpro AS

Arnstein Arnebergsvei 30

1366 Lysaker

Norway

+47 40 00 42 79

E-mail: